Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brands: INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Paliperidone palmitate is a long-acting injectable prodrug of paliperidone with multiple interval options: monthly (PP1M), every 3 months (PP3M), and every 6 months (PP6M), depending on product and prior stabilization.
In the U.S., paliperidone palmitate products are used for schizophrenia maintenance, and the monthly formulation is also labeled for schizoaffective disorder. Longer-interval options are usually introduced after sustained stability on a shorter interval.
Pharmacology mirrors paliperidone/risperidone-class D2/5-HT2A blockade: prolactin elevation and EPS are frequent clinical constraints, and metabolic monitoring remains important.
Because renal excretion is the dominant clearance pathway, renal function meaningfully influences dosing and eligibility for longer intervals.
Paliperidone palmitate is widely used when teams want a predictable depot schedule with limited hepatic interaction complexity. The trade-offs are a higher prolactin signal and meaningful EPS risk in some patients, plus a strong dependence on renal function for dose selection.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Paliperidone (the active drug released from paliperidone palmitate) is a dopamine D2 and serotonin 5-HT2A antagonist and is the major active metabolite of risperidone.
Therapeutic effect is generally attributed to sustained D2 receptor occupancy with serotonergic modulation, while prolactin elevation and EPS reflect dopamine blockade in pituitary and nigrostriatal pathways.